Previous studies have revealed that MYB-NFIB and MYBL1-NFIB fusions are major alterations in this carcinoma, accounting for approximately 50% and 10% of AdCC cases, respectively [3–7]. This evidence concerns the gene MYBL1 and adrenocortical carcinoma, hereditary.